| http://www.w3.org/ns/prov#value | - Scribblers at Goldman Sachs reiterated their ???conviction buy??? rating and ??23.00 price target on the blue-chip drug maker, which develops treatments for rare diseases and conditions such as attention deficit hyperactivity disorder (ADHD).
|
